About the trial

What is the aim of the AbVax study?

The AbVax study is looking at some new types of treatment in HIV. These treatments are being tested to see if they can keep your viral load undetectable without medication. Your viral load is the amount of virus in your blood. This is usually controlled using antiretroviral therapy, or ‘ART’.

The study will look at what happens to the HIV virus and immune system in blood samples. It will also measure how long the viral load stays undetectable without ART. When HIV becomes detectable in a blood test (viral rebound) you will be asked to re-start your ART

Who is eligible to participate?

AbVax is open to people aged 18 to 64 who are living with HIV.

You need to be on antiretroviral therapy (ART) with an undetectable viral load for more than a year.

Before joining the study, you will be tested to see whether you are likely to respond to the treatment.

Your current ART prescription might be switched to a different combination before starting the study. This is because the study includes stopping ART for a short time. Being on the new ART before stopping will make the pause in medication safer.

At the start of the study, your physician will carry out some tests to check if you can join the study. This includes medical history, examination, and blood tests.

How many people will take part?

The study will enrol 48 people from several HIV centres in the UK.

For full information on this trial - please see the AbVax Participant Information Sheet (PIS)